Malignant Fibrous Histiocytoma

Outcome of MFH is associated with the genetic profiles of the primary tumors

Published in Cancer Gene Therapy Week, October 13th, 2003

Outcome of malignant fibrous histiocytomas (MFH) is associated with the genetic profiles of the primary tumors.

"In this study, a panel of 39 primary malignant fibrous histiocytomas (MFH) of high malignancy grade were characterized for chromosomal alterations. The results were then evaluated in relation to the survival and the occurrence of recurrent disease during follow-up for an average period of 63 months," researchers in Sweden report.

"Chromosomal alterations detected by comparative genomic hybridization (CGH) were recorded in 37 of the 39 cases analyzed. The most frequent CGH abnormalities were gains of 17p, 20q, 16p, 17q, 1p31, 7q21, and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Gene Therapy Week

Source: Cancer Gene Therapy Week (2003-10-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry